Alessandra GraziottinAlessandra Graziottin
Condividi su

Angeliq© - A new HRT

Graziottin A.
Angeliq© - A new HRT
Proceedings of the 12th World Congress of Human Reproduction, International Academy of Human Reproduction, Venice, March 10-13, 2005
CIC Edizioni Internazionali, Roma, p. 694, 2005

Angeliq® is an oral, continuous combined hormone replacement therapy (HRT) containing 17β-estradiol 1 mg and the novel progesterone drospirenone (DRSP) 2 mg. Several large-scale trials have demonstrated the efficacy and safety of Angeliq® in almost 600 post-menopausal women.


Available documents:
Full text of the article

By courtesy of CIC Edizioni Internazionali

FAIR USE: The content of this paper can be downloaded, printed and read for strictly personal and non-profit use. Any citation for didactic and/or scientific purpose must quote the title of the document, the name of the author(s), the data of the book or journal, and the URL of the site (

WARNING: Every therapy must be discussed, tailored, prescribed and monitored by the M.D. personally consulted. Every information presented in this website can not surrogate the personal relationship with the caring physician nor be utilized without specific medical advice.